## 3 Results
### Patient and Disease Characteristics  
In the overall M2S-AD population, the median AD-affected body surface area was 30.0% (22.0% in m-AD and 40.0% in s-AD patients), and the median EASI score was 16.9 (12.6 in m-AD and 26.0 in s-AD) (Table 1). Approximately half of the patients included reported adult-onset AD. Interestingly, both the mAD and sAD subgroups reported a median of three flare per year (defined as aggravation of symptoms requiring additional treatment), and one out of six reported more than ten flare-ups per year. Detailed patient and disease characteristics for m-AD, s-AD, and M2S-AD, as defined by the EASI scale, are summarized in Table 1, including predefined physician-diagnosed comorbidities of interest as reported by the patients. The majority of patients suffering both from m-AD and s-AD reported at least one allergic comorbidity, the most common being allergic rhinitis. Notably,one out of five and one out of three patients with m-AD and s-AD, respectively, reported suffering from clinician-diagnosed depression or anxiety disorder.  
\begin{table}
\begin{tabular}{l l c c c} \hline  & & **Overall** & **m-AD** & **s-AD** \\  & & **(N = 184)** & **(N = 117)** & **(N = 67)** \\ \hline
**Sociodemographic and anthropometric characteristics at the study visit \({}^{*}\)** & & & \\ \hline Age (years) & median (IQR) & 38.8 (24.7–52.7) & 39.2 (25.2–52.7) & 38.4 (24.3–52.5) \\  & \textless{65, n (\%)} & 164 (89.1) & 105 (89.7) & 59 (88.1) \\ \hline Female, n (\%) & & 94 (51.1) & 64 (54.7) & 30 (44.8) \\ \hline BMI (kg/m\({}^{2}\)), median (IQR) \({}^{**}\) & & 25.0 (22.2–27.8) & 24.8 (21.5–27.9) & 25.3 (22.7–27.2) \\ \hline  & Underweight (BMI \textless{18.5 kg/m}^{2}\) & 4 (2.2) & 3 (2.6) & 1 (1.5) \\  & Normal (18.5 \(\leq\) BMI \textless{25 kg/m}^{2}\) & 87 (47.3) & 57 (48.7) & 30 (44.8) \\ BMI classification, n (\%) & Overweight & 65 (35.3) & 38 (32.5) & 27 (40.3) \\  & (25 \(\leq\) BMI \textless{30 kg/m}^{2}\) & 27 (14.7) & 18 (15.4) & 9 (13.4) \\  & Missing/Not assessed & 1 (0.5) & 1 (0.9) &. \\ \hline Smoking (current), n (\%) & & 52 (28.3) & 30 (25.6) & 22 (32.8) \\ \hline
**Family history and physician-diagnosed comorbidities of interest** & & & & \\ \hline Family history of AD and/or other allergic conditions, n (\%) & 101 (54.9) & 65 (55.6) & 36 (53.7) \\ \hline History of allergic comorbidity (allergic rhinitis/allergic & 109 (59.2) & 65 (55.6) & 44 (65.7) \\ conjunctivitis/asthma/food & Allergic conjunctivitis & 82 (44.6) & 46 (39.3) & 36 (53.7) \\ allergy), n (\%) & Allergic conjunctivitis & 63 (34.2) & 35 (29.9) & 28 (41.8) \\  & Asthma & 46 (25.0) & 24 (20.5) & 22 (32.8) \\  & Food allergy & 27 (14.7) & 15 (12.8) & 12 (17.9) \\ \hline Depression or anxiety disorder, n (\%) & & 49 (26.6) & 25 (21.4) & 24 (35.8) \\ \hline Anxiety disorder, n (\%) & & 42 (22.8) & 23 (19.7) & 19 (28.4) \\ \hline Contact dermatitis, n (\%) & & 41 (22.3) & 26 (22.2) & 15 (22.4) \\ \hline History of Herpes simplex infections, n (\%) & & 33 (17.9) & 21 (17.9) & 12 (17.9) \\ \hline Hypertension, n (\%) & & 27 (14.7) & 17 (14.5) & 10 (14.9) \\ \hline History of skin infections (requiring antibiotics), n (\%) & & 25 (13.6) & 12 (10.3) & 13 (19.4) \\ \hline Depression, n (\%) & & 20 (10.9) & 10 (8.5) & 10 (14.9) \\ \hline Diabetes, n (\%) & & 10 (5.4) & 7 (6.0) & 3 (4.5) \\ \hline Alopecia areata, n (\%) & & 9 (4.9) & 8 (6.8) & 1 (1.5) \\ \hline History of Herpes zoster infections, n (\%) & & 8 (4.3) & 4 (3.4) & 4 (6.0) \\ \hline Inflammatory bowel disease, n (\%) & & 6 (3.3) & 5 (4.3) & 1 (1.5) \\ \hline History of venous thromboembolism ( VTE), n (\%) & & 2 (1.1) &. & 2 (3.0) \\ \hline Cancer, n (\%) & & 1 (0.5) & 1 (0.9) &. \\ \hline History of cerebrovascular accident (stroke), n (\%) & 1 (0.5) & 1 (0.9) &. \\ \hline \end{tabular}
\end{table}
Table 1: Patient and disease characteristics in the overall M2S-AD population and by severity.